Omalizumab for asthma in adults and children

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Normansell, Rebecca ^a   Walker, Samantha ^b,c   Milan, Stephen J ^a   Walters, E Haydn ^d   Nair, Parameswaran ^e,f  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ASTHMA UK   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF TASMANIA   (Australia)

^e MCMASTER UNIVERSITY   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PLACEBO; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY;

ADULT DISEASE; ASTHMA; CHILDHOOD DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INJECTION SITE REACTION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URTICARIA; ADULT; BLOOD; CHILD; CHRONIC DISEASE; IMMUNOLOGY; META ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; CHRONIC DISEASE; HUMANS; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903816429     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003559.pub4     Document Type: Review

References (321)

1. Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. Journal of Asthma 2012;49(2):144-52.
2. Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on markers of asthma impairment in patients with persistent allergic asthma [Abstract]. Journal of Allergy and Clinical Immunology 2011;127(2 Suppl 1):AB84.
3. NCT00870584 . A 26-Week Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma. www.clinicaltrials.gov/show/NCT00870584 (accessed 7 January 2013). [CRS-ID: 4900100000059268]
4. Boulet L-P, Chapman KR, Côté J, Kalra S, Bhagat R, Swystun VA, et al.Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. American Journal of Respiratory and Critical Care Medicine 1997;155:1835-40.
5. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125(4):1378-86.
6. Busse W, Corren J, Lanier BQ, Mcalary M, Fowler-Taylor A, Della Cioppa G, et al.Anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Journal of Allergy and Clinical Immunology 2001;108(2):184-90.
7. Finn A, Gross G, Van Bavel J, Lee T, Windom H, Everhard F, et al.Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. Journal of Allergy and Clinical Immunology 2003;111(2):278-84.
8. Kaiser J. Medical Officer's Efficacy Review: BLA/STN 103976/0. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113459.pdf (accessed 7 January 2013):26-78.
9. Lanier RQ, Busse W, Corren J, Chervinsky P, Bernstein J, McAlary M, et al.Long-term improvement in asthma control and exacerbation frequency is achieved with omalizumab (Xolair) in patients with moderate-severe asthma. ATS International Conference; May 18-23; San Francisco. 2001:185.
10. Luskin AT, Kosinski M, Bresnahan BW, Ashby M, Wong DA. Symptom control and improved functioning: the effect of omalizumab on Asthma-Related Quality of Life (ARQL). Journal of Asthma 2005;42(10):823-7.
11. Massanari M, Deniz Y, Lee J, Kianifard F, Blogg M, Reisner C, Geba GP. Omalizumab improved asthma control and reduced rescue steroid bursts in moderate to severe allergic asthma [Abstract]. XIX World Allergy Organization Congress; Jun 26-Jul 1; Munich. 2005:Abstract 308.
12. Zeldin R, Massanari M, Blogg M, Jimenez P, Geba G. Treatment of moderate severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils [Abstract]. European Respiratory Journal 2007;30(Suppl 51):353s.
13. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al.Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. New England Journal of Medicine 2011;364(11):1005-15.
14. NCT00377572 . Inner-City Anti-IgE Therapy for Asthma. www.clinicaltrials.gov/show/NCT00377572 (accessed 7 January 2013). [CRS-ID: 4900100000059336]
15. CIGE025AFR02 . Double blind placebo controlled study to assess the expression of Fcε1 on blood basophils and dendritic cells in patients with uncontrolled severe persistent allergic asthma after a 16-week omalizumab treatment. www.novctrd.com (accessed 2 October 2010).
16. Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, et al.Omalizumab-induced decrease of FcRI expression in patients with severe allergic asthma. Respiratory Medicine 2010; Vol. 104, issue 11:1608-17.
17. NCT00454051 . Double Blind Placebo Controlled Study to Assess the Expression of IgE on Basophils and Dendritic Cells During Omalizumab Treatment. www.clinicaltrials.gov/show/NCT00454051 (accessed 7 January 2013). [CRS-ID: 4900100000059264]
18. Djukanovic R, Wilson SJ, Kraft M, Jarjour N, Steel M, Chung KF, et al.Effect of treatment with anti-IgE antibody (omalizumab) on airway inflammation in mild atopic asthma [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle C082.
19. Djukanovic R, Wilson SJ, Kraft M, Jarjour N, Steel M, Chung KF, et al.Omalizumab, an anti-IgE antibody, suppresses airway inflammation in mild allergic asthma via a reduction in mast cell surface-associated interlukin-4 [Abstract]. Allergy & Clinical Immunology International 2003, issue Suppl 1:Abstract No: 0-17-3.
20. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al.Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. American Journal of Respiratory & Critical Care Medicine 2004;170(6):583-93.
21. Fahy JV, Flemming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al.The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 1997;155(6):1828-34.
22. Fahy JV, Cochroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, et al.Effect of aerosolized anti-IgE (E25) on airways responses to inhaled allergen in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 1999;160(3):1023-7.
23. Garcia G, Magnan A, Chiron R, Cecile C-B, Berger P, Taille C. A randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185(Meeting Abstracts):A6764. [CRS-ID: 4900100000060645]
24. Garcia G, Magnan A, Chiron R, Girodet P-O, Le Gros VMH. A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma [Abstract]. European Respiratory Journal 2012;40(Suppl 56):856s [4692]. [CRS-ID: 4900100000067961]
25. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al.Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma [Abstract]. Journal of Allergy and Clinical Immunology 2012;129(2 Suppl):AB69 [258].
26. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al.Omalizumab is effective in allergic and nonallergic patients. Journal of Allergy and Clinical Immunology 2013;131(1):110-116e1. [CRS-ID: 4900100000072110]
27. Condemi JJ, Hamilos DL, Hanania NA, Reyes-Rivera I, Rosen KE, Wong D, et al.Efficacy and safety of omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: results of a phase III randomized controlled trial [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A6840.
28. Dorenbaum A, Trzaskoma B, Haselkorn T, Mink D, Chen H, Solari P. Patient characteristics predictive of omalizumab response in EXTRA. Annals of Allergy, Asthma & Immunology 2012;109(Suppl):A54. [CRS-ID: 4900100000068325]
29. Hanania N, Condemi J, Hamilos D, Reyes-Rivera I, Rosen KE, Wong D, et al.Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: results of a phase IIIb randomized controlled trial [Abstract]. European Respiratory Society Annual Congress; September 18-22; Barcelona. 2010:[E5487].
30. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al.Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Annals of Internal Medicine 2011;154(4):573-82.
31. Hanania NA, Wenzel S, Rosen K, Hsieh H-J, Mosesova S, Choy DF, et al.Exploring the effects of omalizumab in allergic asthma. American Journal of Respiratory and Critical Care Medicine 2013;187(8):804-11. [CRS-ID: 4900100000077549]
32. NCT00314574 . A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists. www.clinicaltrials.gov/show/NCT00314574 (accessed 7 January 2013). [CRS-ID: 4900100000059245]
33. CIGE0250011E1 . An open-label extension to assess long-term safety and tolerability of omalizumab treatment in adolescents and adults with severe allergic asthma who participated in the 32-week core study. www.novctrd.com (accessed 10 February 2010).
34. CIGE0250011E3 . An open-label extension study to assess long term safety and tolerability of omalizumab treat-ment in adults and adolescents with severe allergic asthma who participated in the 52 week CIGE025 0011E2 study. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2314 (accessed 7 January 2013).
35. Chuchalin AG, Herbert J, Rolli M, Gao J, Resiner C. Long-term safety and tolerability of omalizumab an anti-IgE monoclonal antibody in patients with severe allergic asthma. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 421.
36. Chung F, Holgate S, O'Brien J, Fox H, Thirlwell J. Inhaled corticosteroid dose reducing effect of omalizumab in patients with controlled severe asthma, according to usage of inhaled long acting beta-agonist. American Academy of Allergy Asthma and Immunology 58th annual meeting. New York, New York, USA. March 1-6. 2002:[726].
37. Hebert J, Chuchalin A, Rolli M, Fox H. Long-term safety and tolerability of omalizumab in adults with severe allergic asthma. American Thoracic Society Meeting 100th International Conference; 2004 May 21-26; Orlando. 2004.
38. Hebert J, Rolli M, Gao J, Reisner C. Omalizumab an anti-IgE monoclonal antibody demonstrates long-term asthma control safety and tolerability in patients with severe allergic asthma [Abstract]. Journal of Allergy and Clinical Immunology 2006;117(2 Suppl 1):S9.
39. Holgate ST, Chuchalin A, Herbert J, Lotvall J, Chung KF, Bousquet J, et al.Omalizumab (Xolair, rhumab-e25) a novel therapy for severe allergic asthma. Proceedings of the ATS 97th International Conference; 2001 May 18-23; San Francisco. 2001:159.
40. Holgate ST, Chuchalin A, Herbert J, Persson G, Chung F, Bousquet J, et al.Omalizumab (rhumab-e25) improves asthma-specific quality of life in patients with severe allergic asthma. Proceedings of the ATS 97th International Conference; 2001 May 18-23; San Francisco. 2001:184; [D31] [Poster: K13].
41. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, et al.Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical Experimental Allergy 2004;34(4):632-8.
42. Kaiser J. Medical Officer's Efficacy Review: BLA/STN 103976/0. http://www.fda.gov (accessed 7 January 2013):99-122.
43. CIGE0250011E1 . An open-label extension to assess long-term safety and tolerability of omalizumab treatment in adolescents and adults with severe allergic asthma who participated in the 32-week core study. www.novctrd.com (accessed 10 February 2010).
44. CIGE0250011E3 . An open-label extension study to assess long term safety and tolerability of omalizumab treatment in adults and adolescents with severe allergic asthma who participated in the 52 week CIGE025 0011E2 study. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2314 (accessed 7 January 2013).
45. Chuchalin AG, Herbert J, Rolli M, Gao J, Resiner C. Long-term safety and tolerability of omalizumab an anti-IgE monoclonal antibody in patients with severe allergic asthma. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 421.
46. Chung F, Holgate S, O'Brien J, Fox H, Thirlwell J. Inhaled corticosteroid dose reducing effect of omalizumab in patients with controlled severe asthma, according to usage of inhaled long acting beta-agonist. American Academy of Allergy Asthma and Immunology 58th Annual Meeting. New York, New York, USA. March 1-6, 2002 2002:[726].
47. Hebert J, Chuchalin A, Rolli M, Fox H. Long-term safety and tolerability of omalizumab in adults with severe allergic asthma. American Thoracic Society Meeting 100th International Conference; 2004 May 21 - 26; Orlando. 2004.
48. Hebert J, Rolli M, Gao J, Reisner C. Omalizumab an anti-IgE monoclonal antibody demonstrates long-term asthma control safety and tolerability in patients with severe allergic asthma. Journal of Allergy and Clinical Immunology 2006;117(2 Suppl 1):S9.
49. Holgate ST, Chuchalin A, Herbert J, Lotvall J, Chung KF, Bousquet J, et al.Omalizumab (Xolair, rhumab-e25) a novel therapy for severe allergic asthma. Proceedings of the ATS 97th International Conference; 2001 May 18-23; San Francisco. 2001:159.
50. Holgate ST, Chuchalin A, Herbert J, Persson G, Chung F, Bousquet J, et al.Omalizumab (rhumab-e25) improves asthma-specific quality of life in patients with severe allergic asthma. Proceedings of the ATS 97th International Conference; 2001 May 18-23; San Francisco. 2001:184.
51. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, et al.Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical Experimental Allergy 2004;34(4):632-8.
52. Kaiser J. Medical Officer's Efficacy Review: BLA/STN 103976/0. www.fda.gov (accessed 7 January 2013):99-122.
53. Berger W, Humbert M, Leighton T, Turk F, Hedgecock S, Ayre G, et al.Asthma patients judged by the physician to have responded to add-on omalizumab therapy have a greater percentage of symptom-free days. Proceedings of the American Thoracic Society; 2006 May 19-24; San Diego. 2006:A591.
54. Bleecker E, Rubinfield A, Hedgecock S, Fox H, Surrey K, Reisner C. Add-on omalizumab therapy significantly improves symptom control and reduces exacerbations in patients with inadequately controlled severe persistent asthma despite GINA 2002 Step 4 therapy irrespective of maintenance oral corticosteroid (OCS) use: INNOVATE. American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego. 2005:B36; Poster: G51.
55. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, et al.Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respiratory Medicine 2007;101(7):1483-92.
56. Brown R, Turk F, Groot M, Dale P. Cost effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma adaptation of INNOVATE and ETOPA data to the Netherlands. European Respiratory Journal 2007;30(Suppl 51):194s.
57. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al.Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16.
58. Humbert M, Berger W, Rapatz G, Turk F. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy 2008;63(5):592-6.
59. Korenblat P, Levy R, Slavin R, Hedgecock S, Fox H, Surrey K. Omalizumab add-on therapy significantly reduces asthma exacerbations in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy: INNOVATE [Abstract]. Journal of Allergy and Clinical Immunology 2005;115(Suppl 2):S76.
60. Korenblat P, Levy R, Slavin R, Hedgecock S, Fox H, Surrey K, Reisner C. Add-on omalizumab therapy significantly reduces severe asthma exacerbations and emergency visits in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy INNOVATE [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005.
61. Korenblat PE, Hegecock S, Surrey K, Fox H. Omalizumab in patients with severe persistent allergic asthma inadequately controlled by GINA step 4 therapy [Abstract]. American Thoracic Society 100th International Conference; May 21-6; Orlando 2004:B37; G88.
62. Lowe P, Jaffe J, Martin C, Brookman L, Fox H. The effect of discontinuing omalizumab therapy on free lgE concentration [Abstract]. Journal of Allergy and Clinical Immunology 2007;119(Suppl 1):S6.
63. Martin C, Freeman P, Blogg M. Pre-treatment specific IgE levels are not useful in predicting a response to omalizumab therapy [Abstract]. Journal of Allergy and Clinical Immunology 2008;21(2 Suppl 1):S171.
64. Massanari M, Kianifard F, Maykut R, Zeldin R, Hedgecock S, Reisner C, et al.Omalizumab reduced need for steroid bursts and improved treatment effectiveness in asthmatics on inhaled salmeterol and fluticasone combination therapy. Journal of Allergy and Clinical Immunology 2006;117(2 Suppl 1):s10.
65. Massanari M, Maykut RJ, Kianifard F, Zeldin RK, Geba GP. Addition of omalizumab improves quality of life in moderate to severe asthmatics receiving fluticasone 500 ug/salmeterol 50ug [Abstract]. Journal of Allergy and Clinical Immunology 2007;119(1 Suppl):S4.
66. Massanari M, Maykut RJ, Zeldin RK, Kianifard F, Geba GP. Addition of omalizumab improves lung function and treatment effectiveness in patients with moderate-severe persistent allergic asthma inadequately controlled with inhaled steroids and long-acting-beta-agonists. Chest 2006;130(109s):4.
67. Massanari M, Zeldin R, Maykut R, Kianifard F, Geba G. Omalizumab improves lung function and treatment effectiveness in patients with moderate-severe asthma receiving fluticasone 500mcg/salmeterol 50mcg. Proceedings of the American Thoracic Society; 19-24 May; San Diego. 2006:A590.
68. Matz J, Melamed I, Ledford D, Hedgecock S, Fox H, Surrey K, Resiner C. Add-on omalizumab therapy significantly improves quality of life in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 treatment, INNOVATE [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[B36; Poster G47].
69. Novartis . Study number 2306. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1601 (accessed 7 January 2013).
70. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. Journal of Allergy and Clinical Immunology 2009;123(1):107-13.
71. Sthoeger ZM, Eliraz A, Asher I, Berkman N, Elbirt D. The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV - the Israeli arm of the INNOVATE study. Israel Medical Association Journal 2007;9(6):472-5.
72. Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pre-treatment specific IgE and the response to omalizumab therapy [Abstract]. European Respiratory Society Annual Congress; 2008 October 4-8; Berlin. 2008.
73. Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy 2009;64(12):1780-7.
74. Bousquet J, Kulus M, Fox H, Blogg M, Fowler-Taylor A, Fernandez-Vidaurre C. Omalizumab therapy reduces asthma exacerbations in children with severe allergic (ige-mediated) asthma irrespective of lung function at baseline [Abstract].. European Respiratory Society Annual Congress; September 12-16; Vienna. 2009:3281.
75. Bridges T, Hebert J, Fowler-Taylor A, Fernandez-Vidaurre C, Berhane I. Omalizumab reduces asthma exacerbations in children (6-<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use [Abstract]. European Respiratory Society Annual Congress; September 12-16; Vienna, Austria. 2009:P1219.
76. CIGE025AIA05 . A 1 year, randomized, double blind, parallel-group, placebo-controlled, multicenter evaluation of efficacy, safety, pharmacokinetics and pharmacodynamics of omalizumab in children (6 - <12 years) with moderate-severe, persistent, inadequately controlled allergic asthma. www.novctrd.com (accessed 10 February 2010).
77. Kulus M, Bridges T, Fowler-Taylor A, Blogg M, Jimenez P. A randomized controlled study of omalizumab in children with moderate to severe persistent allergic asthma [Abstract]. European Respiratory Society Annual Congress; 2008 October 4-8; Berlin.
78. Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Current Medical Research and Opinion 2010;26(6):1285-93.
79. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. Journal of Allergy and Clinical Immunology 2009;124(6):1210-6.
80. Milgrom H, Fink J, Fowler-Taylor A, Fernandez Vidaurre C, Blogg M, Fox H. Safety of omalizumab in children with inadequately controlled moderate-severe allergic (IgE-mediated) asthma [Abstract]. American Thoracic Society International Conference; May 15-20; San Diego. 2009:A2809 [Poster #J36].
81. Milgrom H, Fowler Taylor A, Blogg M, Fernandez Vidaurre C. Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab [Abstract]. European Respiratory Society Annual Congress; Sept 18-22; Barcelona. 2010:[P2642].
82. Milgrom H, Fowler-Taylor A, Fernandez-Vidaurre C, Jayawardene S. Safety of omalizumab therapy in children with allergic asthma [Abstract]. European Respiratory Society Annual Congress; Sept 12-16; Vienna, Austria. 2009:P1214.
83. Milgrom H, Wasserman RL, Fowler-Taylor A, Fernandez Vidaurre C, Blogg M, Fox H. Add-on omalizumab significantly reduces exacerbation rates in children with inadequately controlled moderate-severe allergic (IgE mediated) asthma. American Thoracic Society International Conference; May 15-20, San Diego. 2009:A2767.
84. NCT00079937 . A 1 Year, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6-< 12 Years) With Moderate-Severe, Persistent, Inadequately Controlled Allergic Asthma. www.clinicaltrials.gov/show/NCT00079937 (accessed 7 January 2013). [CRS-ID: 4900100000059304]
85. CIGE025A US23. A 26-week, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the effect of omalizumab on improving the tolerability of specific immunotherapy in patients with at least moderate persistent allergic asthma inadequately controlled with inhaled corticosteroids. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1601 (accessed 7 January 2013).
86. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al.Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. Journal of Allergy and Clinical Immunology 2010;125(2):383-9.
87. NCT00267202 . A 26-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids. www.clinicaltrials.gov/show/NCT00267202 (accessed 7 January 2013). [CRS-ID: 4900100000059306]
88. Metzger WJ, Fick RB, Bush RK, Busse W, Casale T, Chodosh S, et al.Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (rhu MAbE25). Journal of Allergy and Clinical Immunology 1998;101(1):231.
89. Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, et al.Treatment of allergic asthma with monoclonal anti-IgE antibody. New England Journal of Medicine 1999;341(26):1966-73.
90. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Annals of Allergy Asthma & Immunology 2003;91(2):182-8.
91. Buhl R, Soler M, Fox H, Ashby M, McAlary M, Cooper J, et al.Omalizumab (Xolair, rhumab-e25) decreases hospitalisations due to serious asthma exacerbations. Proceedings of the ATS 97th International conference; 2001 May 18-23; San Francisco. 2001:186.
92. Kaiser J. Medical Officer's Efficacy Review: BLA/STN 103976/0. www.fda.gov (accessed 7 January 2013):79-98.
93. Lemanske RF, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002;110(5):e55.
94. Milgrom H, Berger W, Nayak A, et al.Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:36.
95. Milgrom H, Miller SD, Lanier BQ, Fowler-Taylor A, Chen H, Gupta N. Long-term omalizumab therapy is well tolerated in children with moderate-to-severe IgE-medicated asthma. American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005:B36; Poster: G46.
96. Nayak A, Milgrom H, Berger W, Pollard S, Watrous M, Doyle J, et al.Rhumab-E25 (E25) improves quality of life (QOL) in children with allergic asthma [abstract]. American Journal of Respiratory and Critical Care Medicine 2000;161(3 Suppl):A504.
97. NCT00096954 . A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT). Http://clinicaltrials.gov/show/NCT00096954 (accessed 7 January 2013). [CRS-ID: 4900100000059328]
98. CIGE025AFR05 A 16-Week Treatment, Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of Omalizumab on the Expression of FcÎμRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-Atopic Asthma, Uncontrolled Despite Optimal Therapy. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=5323 (accessed 7 January 2013).
99. NCT01007149 . A 16-Week Treatment, Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of Omalizumab on the Expression of FcÎμRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-Atopic Asthma, Uncontrolled Despite Optimal Therapy. www.clinicaltrials.gov/show/NCT01007149 (accessed 7 January 2013). [CRS-ID: 4900100000059237]
100. CIGE025A1304 . Multicenter, randomized, double-blind, parallel-group, placebo-controlled study with a 16-weektreatment phase to determine the efficacy, safety and tolerability of subcutaneous omalizumab at a dose of at least 0.016mg/kg/IgE[IU/ml] every 2 or 4 weeks for the treatment of patients with moderate to severe bronchial asthma. The trial consisted of 3 periods: a 2-week screening period, a16-week treatment period and a 24-week post-treatment follow-up period. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2197 (accessed 7 January 2013).
101. NCT00232050 . Study of Omalizumab in Moderate to Severe Bronchial Asthma. www.clinicaltrials.gov/show/NCT00232050 (accessed 7 January 2013). [CRS-ID: 4900100000059318]
102. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 2009;14(8):1156-65.
103. Ohta K, Miyamoto T, Yamamoto M, Fox H, Blogg M. Omalizumab improves lung function in asthmatic smokers with severe persistent allergic asthma. American Thoracic Society International Conference; 18-23 May; San Francisco. 2007:Poster F76.
104. Bruno L, Prieto L, Gutierrez V, Colas C, Tabar AI, Perez-Frances, et al.Effect of omalizumab on adenosine 5'-monophosphate responsiveness in allergic asthma [Abstract]. XIX World Allergy Organization Congress; Munich. 2005:Abstract 306.
105. CIGE025AES01 . Effect of omalizumab on bronchial responsiveness to adenosine 5'-monophosphate (AMP) in patients with asthma. www.novctrd.com (accessed 2 October 2010).
106. Prieto L, Gutierrez V, Colas C, Tabar A, Perez-Frances C, Bruno L, et al.Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma. International Archives of Allergy and Immunology 2006;139(2):122-31.
107. Boulet LP, Canonica GW, Dahl R, Hedgecock S, Blogg M, Surrey K, et al.Omalizumab, an Anti-IgE antibody, provides parallel improvements in symptoms of allergic asthma and perennial allergic rhinitis in patients with both diseases: the SOLAR study. Chest 2003;124(4):105s.
108. CIGE025A2304 . A phase IIIb, multicenter, randomized, double-blind, parallel-group, placebo-controlled study with a 28-week treatment phase to determine the efficacy, safety and tolerability of subcutaneous omalizumab for the treatment of 12-75 year-old patients with comorbid moderate-to-severe allergic asthma and perennial allergic rhinitis. www.novctrd.com (accessed 10 February 2010).
109. Dahl R, Ayres J, Hedgecock S, Blogg M, Surrey K, Fox H. Efficacy of omalizumab, an anti-IgE antibody, in patients with concomitant moderate-severe allergic asthma and persistent allergic rhinitis [Abstract]. Journal of Allergy and Clinical Immunology 2004;113(Suppl 2):S37.
110. Hanf G, Noga O, Brachmann I, Kleine-Tebbe J, Rosseau S, Suttorp N, et al.Omalizumab (rhuMAb-E25) inhibits the IgE in vitro release of stimulated PBMC of allergic asthmatics. American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005:B36; Poster: G58.
111. Harnest U, Boulet L, Hedgecock S, Blogg M, Surrey K, Fox H. Omalizumab, an anti-IgE antibody, improves both asthma and rhinitis-related quality of life in patients with concomitant moderate-severe disease [Abstract]. Journal of Allergy and Clinical Immunology 2004;113(Suppl 2):S175.
112. Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009;64(1):81-4.
113. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al.Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. Journal of Allergy & Clinical Immunology 2006;117(6):1493-9.
114. Noga O, Hanf G, Brachmann I, Rosseau S, Suttorp N, Kunkel G. Omalizumab (rhuMAb-E25) induced apoptosis of eosinophils in allergic asthmatics [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005:B36; Poster: G59.
115. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al.Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59(7):709-17.
116. Vignola M, Bousquet J, Maspero J, Fox H, Hedgecock S, Blogg M. Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti IgE agent omalizumab [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: [1388].
117. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125(4):1378-86.
118. Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, et al.The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. European Respiratory Journal 2002;20(5):1088-94.
119. Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, et al.Omaliziumab provides long-term control in patients with moderate-to-severe allergic asthma. European Respiratory Journal 2002;20:73-8.
120. Kaiser J. Medical Officer's Efficacy Review: BLA/STN 103976/0. www.fda.gov (accessed 7 January 2013):26-78.
121. Luskin AT, Kosinski M, Bresnahan BW, Ashby M, Wong DA. Symptom control and improved functioning: the effect of omalizumab on Asthma-Related Quality of Life (ARQL). Journal of Asthma 2005;42(10):823-7.
122. Massanari M, Deniz Y, Lee J, Kianifard F, Blogg M, Reisner C, et al.Omalizumab improved asthma control and reduced rescue steroid bursts in moderate to severe allergic asthma [Abstract]. XIX World Allergy Organization Congress, June 26-July 1, Munich, Germany. 2005:308.
123. Soler M, Buhl R, Bensch O, Noga O, O'Brien J, Champain K, et al.Omalizumab (Xolair rhuMAb-E25) treatment reduces inhaled corticosteroid use in moderate/severe allergic asthma. Proceedings of the ATS 97th International Conference; 18-23 May; San Francisco. 2001:183; [D31] [Poster: K11].
124. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al.The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal 2001;18:254-61.
125. Solèr M, Matz J, Townley RG, Buhl R, O'Brien J, Fox HG, et al.rhuMAb-E25, a novel therapy for the treatment of allergic asthma (AA). European Respiratory Journal 2000;16(Suppl 31):10s.
126. Zeldin R, Massanari M, Blogg M, Jimenez P, Geba G. Treatment of moderate severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils [Abstract]. European Respiratory Journal 2007;30(Suppl 51):353s.
127. Rabe KF, van Rensen ELJ, Evertse CE, van Schadewijk WAA, van Wijngaarden S, Ayre G, et al.Anti-IgE induced changes in bronchial high affinity IgE receptor expressing cells and eosinophils in biopsies in patients with asthma role of DC-SIGN [Abstract]. American Thoracic Society International Conference; May 16-21; Toronto. 2008:A569.
128. van Rensen EL, Evertse CE, Gauw SA, Ayre G, Sterk PJ, Rabe KF. Anti-IgE treatment improves lung function in patients with mild persistent allergic asthma. Journal of Allergy and Clinical Immunology 2006;117(2 Suppl 1):S9.
129. van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, et al.Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009;64(1):72-80.
130. van Rensen ELJ, Evertse CE, van Schadewijk WAA, van der Veen H, Timmers MC. Anti-IgE omalizumab treatment reduces allergen-induced eosinophilia in biopsies and sputum in patients with asthma. American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005:C12.
131. Anonymous . Anti-IgE for allergic asthma. Hospital Practice 2000;24(2):27-8.
132. Anonymous . Anti-IgE antibody reduces need for glucocorticosteroids [Anti-IgE Antikörper: Bedarf an Glucocorticoiden sinkt]. Deutsche Apotheker Zeitung 2000;140(12):1289-92.
133. Anonymous . Omalizumab appears effective in patients with poorly controlled allergic asthma. Formulary 2003;38(4):197, 203.
134. Ayars AG, Altman LC, Potter-Perigo S, Wight TN, Nair P. Sputum hyaluronan as a biomarker of airway remodeling in severe asthma [Abstract]. Journal of Allergy and Clinical Immunology 2011;127(2 Suppl 1):AB8.
135. Ayars AG, Altman LC, Potter-Perigo S, Radford K, Wight TN, Nair P. Sputum hyaluronan and versican in severe eosinophilic asthma. International Archives of Allergy and Immunology 2013;161(1):65-73. [CRS-ID: 4900100000077338]
136. Babu KS, Arshad SH, Holgate ST. Anti-IgE treatment: an update. Allergy 2001;56:1121-8.
137. Beeh K-M, Pereno R, Chen H, Jimenez P. Adding omalizumab to high dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma [Abstract]. European Respiratory Journal 2006;28(Suppl 50):440s.
138. Berger WE. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Annals of Allergy and Immunology 2002;88:152-60.
139. Bisberg D, Froehlich J, Schoenhoff M, Mendelson J. Multiple administrations of the Anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) reduces free IgE levels in a dose dependent manner in adolescents and children with moderate to severe allergic asthma. Journal of Clinical Pharmacology 1996;36:859.
140. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al.Respiratory syncytial virus and recurrent wheeze in healthy. New England Journal of Medicine 2013;368(19):1791-9. [CRS-ID: 4900100000077900]
141. Bousquet J, Smith N, Peckitt C, Maykut R, Peachey G. The effectiveness of different clinical measures in evaluating response to omalizumab. European Respiratory Society Annual Congress; Sep 18-22; Barcelona. 2010:E3764.
142. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al.Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66(5):671-8.
143. Magyar P, Peckitt C, Maykut R, Peachey G. Persistency of treatment response to omalizumab in patients with severe allergic (ige-mediated) asthma [Abstract]. European Respiratory Society Annual Congress; Sep 12-16; Vienna, Austria. 2009:[E1870].
144. NCT00264849 . A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy. www.clinicaltrials.gov/show/NCT00264849 (accessed 7 January 2013). [CRS-ID: 4900100000059292]
145. Siergiejko Z, Swiebocka E, Peckitt C, Maykut R, Peachey G. Omalizumab improves quality of life in adults and adolescents (≥12 years) with uncontrolled severe allergic asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A6651.
146. Siergiejko Z, Swiebocka E, Peckitt C, Maykut R, Peachey G. Omalizumab reduces healthcare resource utilization in adults and adolescents (≥12 years) with uncontrolled severe allergic asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A5404.
147. Siergiejko Z, Swiebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Current Medical Research and Opinion 2011;27(11):2223-8.
148. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al."Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respiratory Medicine 2009;103(11):1633-42.
149. Buhl R, Soler M, Fox H, Ashby M, McAlary M, Cooper J, et al.Omalizumab (XOLAIR, rhu-MAb-E25), decreases hospitalisations die to serious asthma exacerbations. Proceedings of the Annual Thoracic Society 97th International Conference, May 18-23; San Francisco. 2001:186.
150. Busse WW, Holgate ST, Kerwin EM, Chon Y, Feng JY, Lin JH, et al.A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with moderate to severe asthma. Journal of Allergy and Clinical Immunology 2013;131(2):AB230 [817]. [CRS-ID: 4900100000072654]
151. Castro M, Rubin A, Laviolette M, Hanania NA, Armstrong B, Cox G. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Annals of Allergy Asthma and Immunology 2011;107(1):65-70.
152. Chipps B, Kianifard F, Fernandez VC, Massanari M. Effect of omalizumab on peripheral blood eosinophils in children with moderate-severe persistent allergic asthma [Abstract]. Chest 2009;136(4):35S.
153. CIGE025A1305 . Comparative study of IGE025 with suplatast tosilate (IPD) in patient with Japanese cedar pollen-induced seasonal allergic rhinitis (SAR). www.novctrd.com (accessed 10 February 2010).
154. CIGE025A1306 . Open-label study of IGE025 in patients with Japanese cedar pollen-induced seasonal allergic rhinitis (SAR) for second season administration. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2041 (accessed 7 January 2013).
155. CIGE025A1307 . Long-term study of IGE025 in moderate to severe bronchial asthma. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2266 (accessed 7 January 2013).
156. CIGE025A2208 . Multi-center, open-label, multiple dose study in mild to moderate asthmatics (with IgE/body weight combinations above that in the SmPC dosing table) to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of omalizumab. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2739 (accessed 7 January 2013).
157. CIGE025A2303 . A 52 week treatment, multicenter, randomized, double-blind, parallel-group, placebo controlled study to investigate the effect of omalizumab (rhuMAb-E25) on intestinal geohelminth reinfection in adolescent/ adult patients with allergic asthma and/or perennial allergic rhinitis previously treated with an anti intestinal geohelminth treatment regimen. www.novctrd.com (accessed 10 February 2010).
158. CIGE025AUS23 . A 26-week, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the effect of omalizumab on improving the tolerability of specific immunotherapy in patients with at least moderate persistent allergic asthma inadequately controlled with inhaled corticosteroids. www.novartisclinicaltrials.com (accessed 12 March 2009).
159. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al.A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. American Journal of Respiratory and Critical Care Medicine 2010;181(8):788-96.
160. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al.Lebrikizumab treatment in adults with asthma. New England Journal of Medicine 2011;365(12):1088-98.
161. Corren J, Wood R, Patel D, Zhu J, Yegin A, Dhillon G, et al.Omalizumab efficacy following cat allergen exposure: Rresults from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma. European Respiratory Society Annual Congress; Sep 18-22; Barcelona. 2010:[E3962].
162. Corren J, Wood RA, Patel D, Zhu J, Fish J E. A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy of omalizumab in prevention of bronchoconstriction following environmental aeroallergen exposure [Abstract]. Journal of Allergy and Clinical Immunology 2010;125(2 Suppl 1):AB72.
163. Corren J, Wood RA, Patel D, Zhu J, Yegin A, Dhillon G, et al.Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. Journal of Allergy and Clinical Immunology 2011;127(2):398-405.
164. NCT00495612 . A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-Induced Asthma. www.clinicaltrials.gov/show/NCT00495612 (accessed 7 January 2013). [CRS-ID: 4900100000059255]
165. Demoly P, Bousquet J. Rhu-MAb-E25 reduces but does not abrogate the early and late phase reaction following allergen bronchial challenge. American Journal of Respiratory and Critical Care Medicine 1997;155(6):1825-7.
166. Eckman JA, Sterba PM, Kelly D, Alexander V, Liu MC, Bochner BS, et al.Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. Journal of Allergy and Clinical Immunology 2010;125(4):889-95.
167. Emmrich P, Kruse K, Reinhardt D. Anti-IgE antibodies in the treatment of acute asthma [Asthmatherapie mit Anti-IgE Antikörpern]. Monatsschrift für Kinderheilkunde 2001;149(5):506.
168. Ayres G, Anthonissen C, Martin C, Turk F, Thomas K. Assessment of a responder identification treatment algorithm for omalizumab is a naturalistic setting. European Respiratory Journal 2007;30(Suppl 51):623s.
169. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59(7):701-8.
170. Ayres JG, Niven R, Ayre G, Blogg M, Fox H. Omalizumab reduces the rate asthma deterioration related incidents in patients with poorly controlled allergic asthma [Abstract]. Journal of Allergy and Clinical Immunology 2003;111(Suppl 2):S202.
171. Bousquet J, Ayres G, Blogg M. Omalizumab added to best standard care reduces exacerbations in patients with severe persistent asthma according to GINA 2002 classification [Abstract]. European Respiratory Journal 2004;24(Suppl 48):220s.
172. Bousquet J, Niven R, Ayre G, Fox H, Bogg M. Efficacy of omalizumab in patients with moderate to severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4 [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: 1389.
173. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62(2):149-53.
174. Brown R, Turk F, Groot M, Dale P. Cost effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma adaptation of INNOVATE and ETOPA data to the Netherlands. European Respiratory Journal 2007;30(Suppl 51):194s.
175. CIGE025IA04E . A 52-week randomized, open-label, controlled, multi-center study to evaluate efficacy and tolerability of subcutaneous administration of omalizumab in patients with poorly controlled moderate-to-severe allergic asthma in a naturalistic setting. www.novctrd.com (accessed 10 February 2010).
176. CIGE025IA04E2 . A two year open-label extension study to assess long term safety and tolerability of omalizumab treatment in poorly controlled moderate to severe allergic asthma patients who participated in the 52-week CIGE025IA04E1 study. www.novctrd.com (accessed 10 February 2010).
177. Chilvers E, Howes T, Izquierdo JL, Blogg M, Oshinyemi K, Ayre G, et al.Anti-IgE therapy with omalizumab Improves lung function in patients with poorly controlled allergic asthma [abstract]. American Thoracic Society 99th International Conference; May 16-21; Seattle. 2003:C104; Poster D38.
178. Chipps B, Kim K, Korenblat P, Deniz Y, Zberg B, Caroll A. Effect of omalizumab on healthcare utilization in patients with moderate to severe allergic asthma [Abstract]. Journal of Allergy and Clinical Immunology 2003;111(Suppl 2):S144.
179. Chung F, Kunkel G, Ramos S, Ayre G, Fox H, Blogg M. Anti IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate to severe allergic asthma [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: 1390.
180. Higgins B, Britton M, Carrillo T, Oshinyemi K, Blogg M. Anti-IgE therapy with omalizumab improves asthma related quality of life of patients with poorly controlled allergic asthma [Abstract]. Journal of Allergy and Clinical Immunology 2003;111(Suppl 2):S144.
181. Howes T, Izquierdo JL, Chilvers E, Blogg M, Oshinyemi K, Ayre G, et al.Omalizumab, an anti-IgE antibody, decreases exacerbations in patients with poorly controlled allergic asthma. American Thoracic Society 99th International Conference; May 16-21; Seattle. 2003:C104; Poster D39.
182. Kaiser J. Medical Officer's Efficacy Review: BLA/STN 103976/0 (Study IA04). www.fda.gov (accessed 7 January 2013):136-45.
183. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. 2008411524. Respiratory Medicine 2008;102(10):1371-8.
184. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Efficacy of omalizumab in patients with inadequately controlled severe persistent allergic (IgE-mediated) asthma: a subgroup analysis of an open label trial. American Thoracic Society International Conference; May 18-23; San Francisco. 2007:414.
185. Fernandez C, Busse W, Resiner C, Gupta N. Clinical data do not suggest a casual relationship between omalizumab therapy and cancer. American Thoracic Society 2005 International Conference; May 20-25; San Diego. 2005:[B36; Poster: G50].
186. Frew AJ. Effects of anti-IgE in asthmatic subjects. Thorax 1998;53(Suppl 2):52-7.
187. Gauvreau G, Boulet L-P, Cockcroft D, Davis B, Fitzgerald M, Leigh R, et al.Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma [Abstract]. European Respiratory Journal 2012;40(Suppl 56):547s [3087]. [CRS-ID: 4900100000067962]
188. Gauvreau G, Boulet L-P, Cockcroft DW, Davis B, Fitzgerald MJ, Leigh R. Effect of an anti-M1 prime monoclonal antibody, MEMP1972A, in a phase II proof-of-activity allergen challenge study in patients with mild asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012; Vol. 185, issue Meeting Abstracts:A6793. [CRS-ID: 4900100000060646]
189. Gober LM, Sterba PM, Eckman JA, Saini SS. Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients [Abstract]. Journal of Allergy and Clinical Immunology 2008;21(2 Suppl 1):S147.
190. Gossage D, Geba G, Gillen A, Le C, Molfino N. A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5R? monoclonal antibody, in adult asthmatics. European Respiratory Society Annual Congress; Sep 18-22; Barcelona. 2010:[P1177].
191. Gossage DL, Laviolette M, Gauvreau GM, Leigh R, Kolbeck R, Wu Y. Depletion of airway eosinophils by benralizumab an anti-IL5 receptor alpha monoclonal antibody [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185(Meeting Abstracts):A3961. [CRS-ID: 4900100000060605]
192. Hanania NA, Lemanske RFJr, Korenblat PE, Arron JR, Harris JM, Su Z, et al.Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam. 2011; Vol. 38, issue 55:608s [3426].
193. Hendeles L, Khan Y, Massanari M, Spencer T, Shuster J, Chesrown S. The effect of omalizumab on airway responsiveness to adenosine in asthma patients with poor adherence to inhaled steroids. American Thoracic Society International Conference; May 18-23; San Francisco. 2007:Poster #418.
194. NCT00133042 . The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma. www.clinicaltrials.gov (accessed 10 February 2010).
195. Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, et al.A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. British Journal of Clinical Pharmacology 2013;75(1):118-28. [CRS-ID: 4900100000070660]
196. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients at high risk of serious asthma-related morbidity and mortality. Current Medical Research and Opinion 2001;17(4):233-40.
197. Hoshino M. Effects of add-on omalizumab therapy on airway wall thickening in severe persistent asthma. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam 2011;38(55):23s [P267].
198. Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.. Respiration 2012;83:520-8.
199. Hughes TD. Anti-IgE antibody may help treat some asthma patients. Journal of the American Medical Association 2000;284(22):2859-60.
200. Johansson SG, Nopp A, Oman H, Ankerst J, Cardell LO, Gronneberg R, et al.The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy 2009;64(10):1472-7.
201. Kamin W, Kopp M V, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatric Allergy and Immunology 2010;21(1 Pt 2):e160-5.
202. Karpel J, Massanari M, Geba GP, Kianifard F, Inhaber N, Zeldin RK. Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. Annals of Allergy Asthma & Immunology 2010;105(6):465-70.
203. Kenyon NJ, Last MA, Bratt JM, Kwan VW, O'Roark E, Linderholm A. L-arginine supplementation and metabolism in asthma. Pharmaceuticals 2011;4(1):187-201.
204. CIGE025ADE03 . A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of omalizumab in combination with Depigoid, versus Depigoid only, in adult and adolescent patients with seasonal allergic asthma and comorbid seasonal allergic rhinoconjunctivitis - open-label Depigoid monotherapy extension periods 2007and 2008. www.novctrd.com (accessed 10 February 2010).
205. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al.Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clinical and Experimental Allergy 2009;39(2):271-9.
206. NCT00396409 . A Randomized, 20 Week, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Combination With Depigoid, Versus Depigoid Only, in Adult and Adolescent Patients With Seasonal Allergic Asthma and Comorbid Seasonal Allergic Rhinoconjunctivitis - Open-label Depigoid Monotherapy Extension Periods 2007 and 2008. www.clinicaltrials.gov/show/NCT00396409 (accessed 7 January 2013). [CRS-ID: 4900100000059229]
207. Lanier B, Fowler Taylor A, Vidaurre CF, Blogg M. Number needed to treat (NNT) to prevent one exacerbation per year with omalizumab (OMA) In children with inadequately controlled allergic (IgE-mediated) asthma. European Respiratory Society Annual Congress; Sep 18-22; Barcelona. 2010:[P2640].
208. Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, et al.Effect of omalizumab in health care workers with occupational latex allergy. Journal of Allergy and Clinical Immunology 2004;113(2):360-1.
209. Lobo ES, Revicki D, Grant W, Turk F, Massanari M. Assessment of the psychometric properties of the paediatric asthma quality of life questionnaire (PAQLQ) in moderate to severe pediatric asthma patients [Abstract]. Journal of Allergy and Clinical Immunology 2007;119(1 Suppl):S151.
210. Massanari M, Jimenez P, Kianifard F, Maykut R, Zeldin R. The omalizumab associated decrease in peripheral blood eosinophils in moderate severe IgE mediated asthma is sustained following inhaled steroid dose reduction [Abstract]. American Thoracic Society International Conference; May 16-21; Toronto. 2008:A105.
211. Massanari M, Kianifard F, Zeldin RK, Geba GP. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma. Allergy and Asthma Proceedings 2009;30(5):534-9.
212. Massanari M, Sacco P, Kianifard F, Maykut R, Zeldin R. Addition of omalizumab improved functional health status in patients with impaired quality of life associated with moderate to severe persistent allergic asthma [Abstract]. Journal of Allergy and Clinical Immunology 2008;21(2 Suppl 1):S154.
213. Maykut R, Massanari M, Kianifard F, Zeldin R. Effect of omalizumab on asthma control and quality of life in patients with moderate severe persistent IgE-mediated asthma and allergy to house dust mite [Abstract]. Journal of Allergy and Clinical Immunology 2008;21(2 Suppl 1):S157.
214. McClintock D, Corren J, Hanania NA, Mosesova S, Lal P, Arron JR. Lebrikizumab, an anti-IL-13 monoclonal antibody, reduces severe asthma exacerbations over 32 weeks in adults with inadequately controlled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185(Meeting Abstracts):A3959. [CRS-ID: 4900100000060566]
215. Milgrom H, Massanari M, Maykut RJ, Kianifard F, Zeldin RK, Geba GP. Addition of omalizumab reduces school absenteeism in children with moderate to severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology 2007;119(1 Suppl):S150.
216. Milgrom H, Fink J, Fowler-Taylor A, Fernandez Vidaurre C, Blogg M. Safety and tolerability of omalizumab in children with inadequately controlled moderate-to-severe allergic (IgE-mediated) asthma [Abstract]. Thorax 2009;64(Suppl IV):A18 [S31].
217. Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Current Medical Research and Opinion 2011;27(1):163-9.
218. Molfino NA, Bardin PG, Thompson PJ, Luckey A, Yarranton G. A randomized placebo-controlled safety and pharmacodynamic study of KB002, a chimeric anti-GM-CSF monoclonal antibody, in patients with asthma. Journal of Allergy and Clinical Immunology 2013;131(2):AB229 [814]. [CRS-ID: 4900100000072655]
219. Moulton D. Anti-IgE asthma treatment reduces corticosteroid use. Canadian Medical Association 2000;162(6):864.
220. NCT00109187 . Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO). www.clinicaltrials.gov/show/NCT00109187 (accessed 7 January 2013). [CRS-ID: 4900100000059274]
221. NCT00109200 . A Continued Access Protocol to Provide Xolair® (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study. www.clinicaltrials.gov/show/NCT00109200 (accessed 7 January 2013). [CRS-ID: 4900100000059332]
222. The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma. http://ClinicalTrials.gov/show/NCT00133042 (accessed 7 January 2013).
223. NCT00180011 . Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma. www.clinicaltrials.gov/show/NCT00180011 (accessed 7 January 2013). [CRS-ID: 4900100000059296]
224. NCT00189228 . Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma. www.clinicaltrials.gov/show/NCT00189228 (accessed 7 January 2013). [CRS-ID: 4900100000059282]
225. NCT00201097 . Immune Dysregulation in Allergic Asthma. www.clinicaltrials.gov/show/NCT00201097 (accessed 7 January 2013). [CRS-ID: 4900100000059324]
226. NCT00219323 . Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma. www.clinicaltrials.gov/show/NCT00219323 (accessed 7 January 2013). [CRS-ID: 4900100000059272]
227. Bernstein JA. A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma. http://clinicaltrials.gov/show/NCT00242359 (accessed 7 January 2013).
228. NCT00283504 . A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair). www.clinicaltrials.gov/show/NCT00283504 (accessed 7 January 2013). [CRS-ID: 4900100000059316]
229. NCT00287378 . Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab. www.clinicaltrials.gov/show/NCT00287378 (accessed 7 January 2013). [CRS-ID: 4900100000059227]
230. NCT00401596 . A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO). www.clinicaltrials.gov/show/NCT00401596 (accessed 7 January 2013). [CRS-ID: 4900100000059284]
231. NCT00434434 . A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lyophilized and Aged Liquid Omalizumab in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma. www.clinicaltrials.gov/show/NCT00434434 (accessed 7 January 2013). [CRS-ID: 4900100000059320]
232. NCT00482248 . An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study. www.clinicaltrials.gov/show/NCT00482248 (accessed 7 January 2013). [CRS-ID: 4900100000059270]
233. NCT00482508 . A One Year Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Poorly Controlled Moderate to Severe Allergic Asthma Patients Who Participated in the 52-week CIGE24IA04E1 Study. www.clinicaltrials.gov/show/NCT00482508 (accessed 7 January 2013). [CRS-ID: 4900100000059231]
234. NCT00500539 . An Open Label, Single Arm Study to Assess the Safety and Immunogenicity of Omalizumab Liquid Administered Subcutaneously to Male and Female Adolescents and Adults With Persistent Allergic Asthma. www.clinicaltrials.gov/show/NCT00500539 (accessed 7 January 2013). [CRS-ID: 4900100000059223]
235. NCT00546143 . Multi-Center, Open-Label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab. www.clinicaltrials.gov/show/NCT00546143 (accessed on 7 January 2013). [CRS-ID: 4900100000059258]
236. NCT00567476 . A Randomized, Open-Label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing in the Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma. www.clinicaltrials.gov/show/NCT00567476 (accessed 7 January 2013). [CRS-ID: 4900100000059288]
237. CIGE025A2210 . A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2758 (accessed 2 October 2010).
238. NCT00624832 . A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations. www.clinicaltrials.gov/show/NCT00624832 (accessed 8 February 2013). [CRS-ID: 4900100000059239]
239. NCT00639691 . A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab)in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy. www.clinicaltrials.gov/show/NCT00639691 (accessed 7 February 2013). [CRS-ID: 4900100000059266]
240. NCT00777764 . The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients). www.clinicaltrials.gov/show/NCT00777764 (accessed 7 February 2013). [CRS-ID: 4900100000059280]
241. NCT00784485 . Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Treatment With Omalizumab. www.clinicaltrials.gov/show/NCT00784485 (accessed 7 February 2013). [CRS-ID: 4900100000059300]
242. NCT00829179 . Role of RhuMab-E25 in Reducing Exhaled NO in Allergic Asthma. www.clinicaltrials.gov/show/NCT00829179 (accessed 7 February 2013). [CRS-ID: 4900100000059294]
243. NCT01155700 . A 24 Week, Open Label, Multi-center Evaluation of Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment. www.clinicaltrials.gov/show/NCT01155700 (accessed 7 February 2013). [CRS-ID: 4900100000059290]
244. NCT01219036 . The Use of Fractional Exhaled Nitric Oxide (FeNO) and Induced Sputum in the Identification of Non-adherence in Difficult to Control Asthma. www.clinicaltrials.gov/show/NCT01219036 (accessed 7 February 2013). [CRS-ID: 4900100000059247]
245. Nopp A, Johansson SG, Adedoyin J, Ankerst J, Palmqvist M, Oman H, et al.After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010;65(1):56-60.
246. Oh C, Parker J, Geba G, Molfino N. Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma. European Respiratory Society Annual Congress; Sep 18-22; Barcelona. 2010:[377].
247. Oh CK, McLaurin KK, Kim K, Hultquist M, Molfino NA. A phase 2b, randomized study to evaluate the clinical activity and safety profile of subcutaneous MEDI-528, an anti-IL-9 monoclonal antibody, In adults with uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185(Meeting Abstracts):A2760. [CRS-ID: 4900100000060588]
248. Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S, et al.Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. Journal of Allergy and Clinical Immunology 2005;116(3):558-64.
249. Parker J, Brazinsky S, Miller DS, Nayak A, Korenblat PE, Sari S, et al.Randomized, double-blind, placebo-controlled, multicenter phase 2A study to evaluate the effect of a humanized interleukin-9 monoclonal antibody (MEDI-528) on exercise-induced bronchospasm [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A5394.
250. Parker J, Wolansky LJ, Khatry D, Geba GP, Molfino NA. Brain magnetic resonance imaging in adults with asthma. Contemporary Clinical Trials 2011;32(1):86-9.
251. Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, et al.Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulmonary Medicine 2011;11:14.
252. Patel BM, Chiang DT, Clark JP, Romero FA, Casale TB. Effects of omalizumab (Xolair®) on airway hyperresponsiveness [Abstract]. Journal of Allergy and Clinical Immunology 2009;123(2 Suppl 1):S263.
253. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al.Mepolizumab for severe eosinophilic asthma (DREAM). Lancet. England, 2012; Vol. 380, issue 9842:651-9. [CRS-ID: 4900100000063432]
254. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al.Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam. 2011; Vol. 38, issue 55:608s [3425].
255. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al.A phase II placebo-controlled study of tralokinumab in. European Respiratory Journal 2013;41(2):330-8. [CRS-ID: 4900100000073595]
256. Israel E, Cohn J, Meltzer E, McCarty J, Zheng B, Carroll A. Omalizumab does not induce thrombocytopenia in treatment of asthma [Abstract]. Journal of Allergy and Clinical Immunology 2003;111(Suppl 2):S146.
257. Kaiser J. Medical Officer's Efficacy Review: BLA/STN 103976/0. www.fda.gov (accessed 7 February 2013):123-36.
258. Riviere GJ, Kuebler P, Jaffe JS, Yeh CM, Reynolds C, Brookman L. A liquid formulation of omalizumab is bioequivalent to the current lyophilized formulation [Abstract]. American Thoracic Society International Conference; May 16-21; Toronto. 2008:A613.
259. Riviere GJ, Abbi S, Koehne-Voss S, Kim K, Jaffe JS. Bioequivalence of a new formulation of omalizumab, solution for injection in prefilled syringe, to the current lyophilized formulation [Abstract]. European Respiratory Society Annual Congress; Sep 12-16; Vienna. 2009:[E1873].
260. Riviere GJ, Yeh CM, Reynolds CV, Brookman L, Kaiser G. Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilized powder formulation. Journal of Bioequivalence and Bioavailability 2011;3(6):144-50.
261. Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). Journal of Asthma 2012;49(3):288-93.
262. Scheerens H, Arron JR, Su Z, Zheng Y, Putnam W, Erickson RW, et al.Predictive and pharmacodynamic biomarkers of interleukin-13 blockade: effect of lebrikizumab on late phase asthmatic response to allergen challenge [Abstract]. Journal of Allergy and Clinical Immunology 2011;127(2 Suppl 1):AB164.
263. Stallings A, McLaughlin A, Murphy D, Carper H, Platts-Mills T, Heymann P. A surveillance study of natural rhinovirus colds in young adults with mild asthma [Abstract]. Journal of Allergy and Clinical Immunology 2009;123(2 Suppl 1):S56.
264. Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, et al.Efficacy of omalizumab in eosinophilic chronic rhinosinusitis. Annals of Allergy Asthma & Immunology 2013;110(5):387-8. [CRS-ID: 4900100000077419]
265. Townley R, Jourd, heuil D, Jourd heuil F, DeMeyere-Coursey K, Mahon L, Romero T, et al.The effects of omalizumab on bronchial and alveolar airway inflammation as measured by exhaled nitric oxide (ENO) in moderate to severe asthmatics [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011;183(Meeting Abstracts):A4478.
266. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al.Dupilumab in persistent asthma with elevated eosinophil levels. New England Journal of Medicine 2013:Epub ahead of print. [CRS-ID: 4900100000076900]
267. Wilson SJ, Ward JA, Jarjoiur NN, Kraft M, Chung KF, Fahy JV, et al.Omalizumab reduces mast cell numbers in airway smooth muscle [Abstract]. American Thoracic Society International Conference; May 16-21; Toronto. 2008:A499.
268. Yalcin AD, Kargi A, Kose S, Terzioglu E, Gorczynski RM. Efficacy of omalizumab and specific subcutaneous immunotherapy in allergic asthma. Respirology 2011;16(Suppl 2):Abstracts (pages 1-326).
269. Zaidi AK, Saini SS, MacGlashan DW Jr. Changes in the Fc-epsilonRI-beta: Fc-epsilonRI-alpha ratio during treatment with omalizumab [Abstract]. Journal of Allergy and Clinical Immunology 2009;123(2 Suppl 1):S193.
270. Zielen S, Lieb A, De Monchy J, De la Motte S, Wagner F, Fuhr R, et al.Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels [Abstract]. European Respiratory Society Annual Congress; Sep 12-16; Vienna. 2009:[E1869].
271. Zielen S, Lieb A, De La Motte S, Wagner F, de Monchy J, Fuhr R, et al.Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E--mediated) asthma. International Archives of Allergy and Immunology 2013;160(1):102-10. [CRS-ID: 4900100000072111]
272. Creticos PS, Saini SS, Scarupa MD, Balcer-Whaley SL, Bieneman AP, Schroeder JT. Effects of omalizumab in non-allergic asthma [Abstract]. Journal of Allergy and Clinical Immunology 2010;125(2 Suppl 1):AB197.
273. NCT00162773 . Effect of Anti-IgE in Non-Allergic Asthma. www.clinicaltrials.gov/show/NCT00162773 (accessed 7 February 2013). [CRS-ID: 4900100000059276]
274. CIGE025A2306 28-Wk, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Efficacy, Safety, Tolerability of Subcutaneous Omalizumab in Adults and Adolescents With Severe Persistent Allergic Asthma Who Remain Inadequately Controlled Despite GINA (2002) Step 4 Therapy. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1601 (accessed 7 February 2013).
275. NCT00046748 . Ph III, 28-Wk, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Efficacy, Safety, Tolerability of SC Omalizumab in Adults and Adolescents w/ Severe Persist. Allergic Asthma & Are Inadequately Controlled Despite GINA (2002) Step 4 Tx. www.clinicaltrials.gov/show/NCT00046748 (accessed 7 February 2013). [CRS-ID: 4900100000059298]
276. NCT00226200 . Soluble CD23 Expression as a Marker of Immunomodulation and Clinical Response in Asthma Patients Treated With Omalizumab. www.clinicaltrials.gov/show/NCT00226200 (accessed 7 February 2013). [CRS-ID: 4900100000059260]
277. NCT00329381 . A 26-Wk, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, Multi-Centered Study to Evaluate the Effect of Xolair (Omalizumab) on Improving the Tolerability of Spec. Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled with Inhaled Corticosteroids. www.clinicaltrials.gov/show/NCT00329381 (accessed 7 February 2013). [CRS-ID: 4900100000059243]
278. NCT00367016 . Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma). www.clinicaltrials.gov/show/NCT00367016 (accessed 7 February 2013). [CRS-ID: 4900100000059310]
279. NCT00495612. A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-Induced Asthma (AERO). www.clinicaltrials.gov/ct2/show/NCT00495612 (accessed 7 February 2013).
280. CIGE025A2432 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-Agonists. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=7463 (accessed 7 February 2013).
281. NCT00670930 . A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Explore the Effects of 78 Weeks Omalizumab Treatment Given as Add on Therapy on Markers of Airway Inflammation and Remodeling in Patients With Moderate to Severe Persistent Allergic Asthma Receiving Inhaled Corticosteroids and Long Acting Beta-agonists. www.clinicaltrials.gov/show/NCT00670930 (accessed 7 February 2013). [CRS-ID: 4900100000059278]
282. NCT00691873 . A 26-Wk, Randomized, Dble-Blinded, Parallel-Grp, Placebo-Controlled, Multi-Centered Study to Eval the Effect of Xolair (Omalizumab) on Improving the Tolerability of Spec. Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids. www.clinicaltrials.gov/show/NCT00691873 (accessed 7 February 2013). [CRS-ID: 4900100000059262]
283. NCT01393340 . Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma. www.clinicaltrials.gov/show/NCT01393340 (accessed 7 February 2013). [CRS-ID: 4900100000059322]
284. NCT00286416 . Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With the Co-Morbid Conditions of Aspirin Exacerbated Respiratory Disease(AERD) and Allergic Asthma and Rhinitis. www.clinicaltrials.gov/show/NCT00286416 (accessed 7 February 2013). [CRS-ID: 4900100000059312]
285. Scripps Clinic. Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With the Co-morbid Conditions of Aspirin Exacerbated Respiratory Disease (AERD) and Allergic Asthma and Rhinitis (completed). NCT00286416 2009:ClinicalTrials.gov ID: NCT00286416.
286. NCT00139152 . Exhaled Breath Condensate and Nitric Oxide: Non-Invasive Evaluation of Lung Disease After Treatment With Xolair. www.clinicaltrials.gov/show/NCT00139152 (accessed 7 February 2013). [CRS-ID: 4900100000059253]
287. NCT00208234 . The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness. www.clinicaltrials.gov/show/NCT00208234 (accessed 7 February 2013). [CRS-ID: 4900100000059251]
288. NCT00555971 . A Placebo Controlled, Double-Blind Investigation of the Therapeutic Utility of Xolair (Omalizumab) for Attenuating Aspirin Induced Bronchospasm in Patients With Aspirin Exacerbated Respiratory Disease (AERD) Undergoing Aspirin Desentization. www.clinicaltrials.gov/show/NCT00555971 (accessed 7 February 2013). [CRS-ID: 4900100000059326]
289. NCT01113437 . The Effect of a Humanised Monoclonal Anti-IgE Antibody, Omalizumab, on Disease Control and Bronchial Mucosal Inflammation in Non-Atopic Asthma. www.clinicaltrials.gov/show/NCT01113437 (accessed 7 February 2013). [CRS-ID: 4900100000059334]
290. NCT01125748 . A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Persistency of Response With or Without Xolair After Long-Term Therapy. www.clinicaltrials.gov/show/NCT01125748 (accessed 7 February 2013). [CRS-ID: 4900100000059286]
291. NCT01202903 . A 24-Week, Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Xolair® (Omalizumab) in Patients With Moderate to Severe Persistent Allergic Asthma Who Remain Not Adequately Controlled Despite GINA (2009) Step 4 Therapy. www.clinicaltrials.gov/show/NCT01202903 (accessed 7 February 2013). [CRS-ID: 4900100000059249]
292. NCT01430403 . Preventative Omalizumab or Step-Up Therapy for Severe Fall Exacerbations (ICAC-20). www.clinicaltrials.gov/show/NCT01430403 (accessed 7 February 2013). [CRS-ID: 4900100000059308]
293. NCT01544348 . A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects. www.clinicaltrials.gov/show/NCT01544348 (accessed 7 February 2013). [CRS-ID: 4900100000059235]
294. Arshad SH, Babu KS, Holgate ST. Anti-IgE Therapy in Asthma and Allergy. 1st Edition. London: Martin Dunitz, 2001.
295. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125(4):1378-86.
296. British Thoracic Society. British guideline on the management of asthma. www.sign.ac.uk/pdf/sign101.pdf. (accessed 7 February 2013).
297. British Guideline on the Management of Asthma. A National Clinical Guideline. www.sign.ac.uk/guidelines/fulltext/101/ (accessed 7 February 2013).
298. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE and skin test reactivity to allergens. New England Journal of Medicine 1989;320:271-7.
299. Casale TB, Bernstein IL, Busse WW, et al.Use of an anti-IgE humanised monoclonal antibody in ragweed-induced allergic rhinitis. Journal of Allergy and Clinical Immunology 1997;100:110-21.
300. Chen H, Eisner MD, Haselkorn T, Trzaskoma B. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respiratory Medicine 2012 October 18 [Epub ahead of print].
301. Chipps BE, Figliomeni M, Spector S. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Allergy Asthma Proceedings 2012;33(5):377-85.
302. 2012 CTS Guideline Update: diagnosis and management of asthma in preschoolers, children and adults. www.respiratoryguidelines.ca/2012-cts-guideline-asthma-update (accessed 7 February 2013).
303. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2011. www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html (accessed 16 September 2012).
304. Haldar P, Pavord I, Shaw D, Berry M, Thomas M, Brightling C, et al.Cluster analysis and clinical asthma phenotypes. American Journal of Respiratory and Critical Care Medicine 2008;178(3):218-24.
305. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
306. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al.Assessing the quality of reports of randomised controlled trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
307. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. Journal of Clinical Epidemiology 1994;47:81-7.
308. Milgrom H, Fick RB, Su JQ, et al.Treatment of allergic asthma with monoclonal anti-IgE antibody. New England Journal of Medicine 1999;341(26):1966-73.
309. National Institute for Health and Care Excellence. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201). http://www.nice.org.uk/nicemedia/live/14157/63689/63689.pdf (accessed 25 June 2013).
310. Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, et al.Update on optimal use of omalizumab in management of asthma. Journal of Asthma and Allergy 2011;4:49-59.
311. Perret JL, Dharmage SC, Matheson MC, Johns DP, Gurrin LC, et al.The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. American Journal of Respiratory and Critical Care Medicine 2013;187(1):42-8.
312. Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine 1998;339:1030-5.
313. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
314. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relationship between airways responsiveness and serum IgE in children with asthma and in apparently normal children. New England Journal of Medicine 1991;325:1067-71.
315. Spector SL. Allergic inflammation in upper and lower airways. Annals of Allergy Asthma & Immunology 1999;83:435-44.
316. Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clinical Medical Insights. Circulatory, Respiratory and Pulmonary Medicine 2012;6:27-40.
317. Walker S. Omalizumab reduces frequency of asthma exacerbations in children. Journal of Pediatrics 2011;159(3):512-3.
318. Wenzel S, Bousquet J, Holgate S, Freeman P, Fox H. Patients with more severe allergic asthma gain greatest relative benefit from omalizumab therapy. American Journal of Respiratory & Critical Care Medicine. 2002; Vol. 165:A215.
319. Wijnhoven HAH, Kriegsman DMW, Hesselink AE, Penninx BWJH, De Haan M. Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and quality of life. Chest 2001;119(4):1034-42.
320. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annual Review of Immunology 1999;17:255-81.
321. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003559.pub3]